CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®
Boehringer Ingelheim today announced the presentation of several new post-hoc analyses from the TONADO® 1&2 and OTEMTO® 1&2 studies at the American College of CHEST Physicians Annual Meeting in Montreal. One analysis showed significant lung function improvement, as measured by FEV1 AUC0–3, with once daily Spiolto® Respimat® in COPD patients* across a range of age groups, including those over 65 years of age.1 In addition, a second analysis indicated that Spiolto® Respimat® reduces the frequency of night-time rescue medication use, as measured by puffs needed per night2 and these reductions were sustained for up to 52 weeks. In a third analysis the improvement of dyspnea (or shortness of breath), as measured by the Transition Dyspnea Index (TDI), was shown in COPD patients, compared to tiotropium, olodaterol and placebo.3
From early in the course of COPD, decreasing lung function makes it more and more difficult for patients to breathe. When many patients are first diagnosed their condition is already declining rapidly. To cope with feeling breathless, patients reduce their activity and change their lifestyles. Once symptoms start to prevent normal daily activities there is a downward spiral of reduced physical activity leading to worsening symptoms, further dyspnea and even further sedentary behavior.4 This in turn results in a large physical and emotional impact on people living with the disease.5
“The post-hoc data presented at the CHEST meeting demonstrate that Spiolto® Respimat® may provide improvement across several important clinical outcomes. These results further support the evidence of the benefit of using Spiolto® Respimat® in patients requiring COPD maintenance treatment. Providing optimal treatment right from the start of maintenance therapy can give patients the best chance of managing their symptoms, keeping active and limiting their need for rescue medication ”, said Dr William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim.
The most common adverse events in the TONADO® 1&2 and OTEMTO® 1&2 studies were nasopharyngitis (common cold), cough and back pain.
For more information see US press release: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2015/10-27-2015-new-sub-analyses-presented-stiolto-respimat-across-range-patient-reported-outcomes-measures.html
For further information visit: http://newscentre.boehringer-ingelheim.com/education_hub1/respiratory.html
OTEMTO® Respiratory Medicine publication: http://dx.doi.org/10.1016/j.rmed.2015.08.002
For ‘Notes to Editors’ and ‘References’ please visit: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/28_october_2015_copd.html
* Patients requiring maintenance treatment
Dr. Kristin Jakobs, Media & PR
Phone +49 6132 77 144553
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
DXC Technology Named a 2018 Thomson Reuters Top 100 Global Technology Leader18.1.2018 23:12 | Pressemelding
DXC Technology (NYSE: DXC) has been recognized as a 2018 Top 100 Global Technology Leader by Thomson Reuters. The inaugural program identifies the tech industry’s most operationally sound and financially successful organizations. The Thomson Reuters Top 100 Global Tech Leaders study, the industry’s first holistic assessment of today’s leading tech companies, utilizes a 28-point data-driven algorithm to objectively identify organizations positioned to thrive in a complex and changing business environment. The patent pending methodology, developed by the Thomson Reuters Boston Innovation Lab, is based on eight principal pillars of performance: Financial Performance, Management and Investor Confidence, Risk and Resilience, Legal Compliance, Innovation, People and Social Responsibility, Environmental Impact, and Reputation. According to Thomson Reuters, these are the companies whose final scores across the pillars outshine over 5,000 other technology companies around the world. “DXC Techno
IFF Honors Dominique Ropion with Prestigious Master Perfumer Title18.1.2018 21:15 | Pressemelding
Regulatory News: This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180118006275/en/ Dominique Ropion (Photo: Business Wire) International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, has named Dominique Ropion Master Perfumer. The Company’s designation recognizes perfumers who have demonstrated consistent and outstanding levels of creativity and craftsmanship in the art of perfumery, and exceptional leadership in and measurable impact on the industry. Mr. Ropion is the second perfumer at IFF recognized with the prestigious title, which was established in 2013. “At the heart of IFF are the people who consistently go above and beyond to passionately pursue their art and by doing so, revolutionize the industry,” said IFF Chairman & CEO Andreas Fibig. “In his 17 years with us, Dominique has consistently achieved this outstanding level of creativity and p
The Securities & Exchange Commission Announces Several Judgments And Injunctions Entered Against Defendants In The SEC v. Benger, et al. Litigation18.1.2018 19:21 | Pressemelding
The following statement is being issued by the Securities & Exchange Commission regarding Benger Fair Fund Class Action: Legal Notice BENGER FAIR FUND NOTICE The United States Securities and Exchange Commission authorized this Notice. This is not a solicitation from a lawyer. If you purchased or otherwise acquired China Voice Holding Corp., Biomoda, Inc., Pharma Holdings Inc., World Energy Solutions, Inc., Revolutions Medical Corp., Earthsearch Communications, Inc., and Essential Innovations Technology Corp. common shares from Defendants outside of the United States between March 1, 2007 and February 28, 2009, inclusive (the “Relevant Period”), you may be entitled to receive a monetary payment from the Benger Fair Fund (“Fair Fund”). Background In the action titled Securities and Exchange Commission v. Benger, et al. pending in the United States District Court for the Northern District of Illinois, Case No. 09-CV-676, several judgments and injunctions were entered against defendants Ha
Pharnext’s Pivotal Phase 3 Trial PLEO-CMT to Be Featured at the 22nd Edition of the Francophone Peripheral Nerve Society Conference18.1.2018 16:45 | Pressemelding
Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced the Company will present an update from its ongoing pivotal Phase 3 clinical trial PLEO-CMT evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), in an oral session during the 22nd edition of the Francophone Peripheral Nerve Society conference. The gathering will take place on January 26-27, 2018 in Paris (France). Details of the presentation are as follows: Date Time Session Friday January 26, 2018 From 3:03 to 3:15pm CET Selected Oral Communications Session Title: Status of the Pivotal Phase III Study (PLEO-CMT) Assessing the Efficacy and Safety of PXT3003 in the Treatment of Adult Patients with Charcot-Marie-Tooth type 1A Speaker : Prof. Shahram Attarian (Marseille) For more information about the event please visit : www.
ExaGrid Selected as Finalist for Storage Magazine’s 2017 “Product of the Year – Backup and DR Hardware” Award18.1.2018 16:45 | Pressemelding
ExaGrid®, a leading provider of hyper-converged secondary storage for backup, today announced that its EX Series of backup storage appliances with data deduplication has once again been selected as a finalist for TechTarget’s Storage magazine/SearchStorage.com 2017 “Product of the Year” award in the “Backup and DR Hardware” category. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180118006039/en/ These annual awards, now in their 16th year, showcase the year’s latest and greatest innovations in technology. “These premier awards are of particular import as the panel of judges are genuine experts in an increasingly complex segment of data center technology,” said Bill Andrews, CEO and President of ExaGrid. “To have been selected given their stringent criteria is an honour of which we’re quite proud.” Only ExaGrid uses a scale-out architecture with a unique loading zone, which addresses all of the scalability and performance cha
Piraeus Bank Completes the Sale of a Portfolio of €0.2bn of Romanian Originated Loans to Kruk Group18.1.2018 16:22 | Pressemelding
Piraeus Bank SA, in conjunction with Piraeus Bank Romania (together “the Bank”), have completed the sale of a portfolio of €0.2bn of Romanian originated loans to Kruk Group. The sale, together with sales of Romanian loans of €0.4bn in previous periods, have been part of the Bank’s focused and systematic actions, targeted to fulfill its restructuring plan obligations, NPE operational targets and de-risk its balance sheet. View source version on businesswire.com: http://www.businesswire.com/news/home/20180118006013/en/ Contact information Media enquiries: Piraeus Bank Group George Papaioannou, Head of Press Office +30 210 3288 830 or Powerscourt Alex Rowbottom +44 (0)20 7250 1446
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom